TY  - GEN
AU  - Contel,Maria
TI  - Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
SN  - books978-3-03921-316-0
PY  - 2019///
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - ?-? stacking
KW  - encapsulation
KW  - n/a
KW  - oxindolimine-metal complexes
KW  - cyclodextrin
KW  - platinum iodido complexes
KW  - distribution coefficient
KW  - antiproliferative activity
KW  - anticancer agents
KW  - nanotubes
KW  - ruthenium
KW  - platinum
KW  - Log kw
KW  - nanoparticles
KW  - drug discovery
KW  - metal complex
KW  - metallodrugs
KW  - isatin-derived ligands
KW  - anticancer drug
KW  - upconverting nanoparticles
KW  - pyridine benzimidazole
KW  - dendrimers
KW  - liposomes
KW  - thiophene
KW  - angiogenesis
KW  - micelles
KW  - HSA oxidation
KW  - platinum(IV)
KW  - imaging
KW  - chromatographic lipophilicity parameter
KW  - amidophosphine
KW  - copper and iron chelators in cancer
KW  - Log P
KW  - biomacromolecules
KW  - bones
KW  - DNA cleavage
KW  - stopped-flow spectroscopy
KW  - silver
KW  - phosphonates
KW  - transmetalation
KW  - metallomics
KW  - MRI
KW  - fluorescence quenching
KW  - partition coefficient
KW  - gold fingers
KW  - anticancer
KW  - HSA binding
KW  - gold
KW  - ?0
KW  - targeting
KW  - metastasis
KW  - DNA interaction
KW  - antimigration
KW  - cytotoxicity
KW  - HPLC
KW  - ruthenium complexes
KW  - zinc finger proteins
KW  - Gold(III) complexes
KW  - aquaporins
KW  - antiproliferative
KW  - protein-DNA recognition
KW  - photoactivation
KW  - lipophilicity
KW  - cancer
KW  - 1-methylcytosine
KW  - PET
N1  - Open Access
N2  - For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile
UR  - https://mdpi.com/books/pdfview/book/1637
UR  - https://directory.doabooks.org/handle/20.500.12854/61518
ER  -